GLP 1 RA and Fat Hyperplasia

In this episode, we explore the risks and scientific concerns surrounding GLP-1 receptor agonists, such as Wegovy and Zepbound, which are reshaping the weight loss and diabetes treatment markets. While these drugs show significant weight loss benefits, research reveals a troubling rebound effect when patients discontinue use, often leading to greater weight regain due to fat cell hyperplasia. Unlike the common yo-yo dieting effect, these medications can increase the number of fat cells in the body, making future weight management more challenging. Dr. Kiernan warns that without lasting lifestyle changes, users may face intensified fat accumulation, particularly in harmful visceral areas, exacerbating health risks.